Last $2.93 USD
Change Today 0.00 / 0.00%
Volume 118.3K
PSTI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
Tel Aviv
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics, Inc. Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

Pluristem Therapeutics Inc. announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial. The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients. In May 2014, Pluristem received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) to use PLX cells in South Korean trials.

Pluristem Therapeutics, Inc. Presents at Barclays Select Series 2014: Israel Biotech/Medtech Corporate Day, May-29-2014

Pluristem Therapeutics, Inc. Presents at Barclays Select Series 2014: Israel Biotech/Medtech Corporate Day, May-29-2014 . Venue: 745 Seventh Avenue, New York, New York, United States. Speakers: Karine Kleinhaus, Divisional Vice President of North- America.

Pluristem Therapeutics Inc. Announces Amendment to the Amended and Restated Articles of Incorporation

Pluristem Therapeutics Inc. at its annual meeting of stockholders on May 22, 2014, approved amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock.

Pluristem Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:30 PM

Pluristem Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Karine Kleinhaus, Divisional Vice President of North- America, Zami Aberman, Executive Chairman and Chief Executive Officer.

Pluristem Receives Clearance from South Korea to Use PLX Cells Manufactured at its New Facility in its Advances Studies

Pluristem Therapeutics, Inc. announced the latest advancement in its clinical and commercial development programs in South Korea. The South Korean Ministry of Food and Drug Safety has recently cleared Pluristem's upgraded manufacturing process in its new facility in Haifa, Israel. The cells produced at Pluristem new facility will be used by Korean sites joining the large Phase II study currently conducted by Pluristem in intermittent claudication (IC) patients. This Phase II IC study is currently ongoing in the U.S., Israel and Germany. Under the terms of the agreement, CHA will perform and fund multiple clinical trials in South Korea using Pluristem proprietary PLX cells. Upon the first regulatory approval for a PLX product in South Korea, Pluristem and CHA will establish a joint venture (JV) co-owned by the parties.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $2.93 USD 0.00

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.63 USD -0.11
Athersys Inc $1.69 USD -0.04
Cardica Inc $1.15 USD -0.01
Cerus Corp $4.02 USD +0.19
Cytori Therapeutics Inc $2.21 USD -0.02
View Industry Companies
 

Industry Analysis

PSTI

Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 505.9x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 365.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.